Logo image of THAR

THARIMMUNE INC (THAR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:THAR - US4327053090 - Common Stock

2.36 USD
-0.24 (-9.23%)
Last: 12/1/2025, 8:00:00 PM
2.4188 USD
+0.06 (+2.49%)
After Hours: 12/1/2025, 8:00:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to THAR. THAR was compared to 534 industry peers in the Biotechnology industry. Both the profitability and financial health of THAR have multiple concerns. THAR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

THAR had negative earnings in the past year.
In the past year THAR has reported a negative cash flow from operations.
In the past 5 years THAR always reported negative net income.
In the past 5 years THAR always reported negative operating cash flow.
THAR Yearly Net Income VS EBIT VS OCF VS FCFTHAR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

With a Return On Assets value of -474.80%, THAR is not doing good in the industry: 96.25% of the companies in the same industry are doing better.
The Return On Equity of THAR (-3269.84%) is worse than 82.58% of its industry peers.
Industry RankSector Rank
ROA -474.8%
ROE -3269.84%
ROIC N/A
ROA(3y)-179.85%
ROA(5y)-342.76%
ROE(3y)-395.91%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
THAR Yearly ROA, ROE, ROICTHAR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for THAR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
THAR Yearly Profit, Operating, Gross MarginsTHAR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for THAR has been increased compared to 1 year ago.
The number of shares outstanding for THAR has been increased compared to 5 years ago.
There is no outstanding debt for THAR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
THAR Yearly Shares OutstandingTHAR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
THAR Yearly Total Debt VS Total AssetsTHAR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

THAR has an Altman-Z score of -13.20. This is a bad value and indicates that THAR is not financially healthy and even has some risk of bankruptcy.
THAR has a worse Altman-Z score (-13.20) than 77.53% of its industry peers.
THAR has a Debt/Equity ratio of 0.68. This is a neutral value indicating THAR is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.68, THAR is doing worse than 73.03% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF N/A
Altman-Z -13.2
ROIC/WACCN/A
WACCN/A
THAR Yearly LT Debt VS Equity VS FCFTHAR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

THAR has a Current Ratio of 1.17. This is a normal value and indicates that THAR is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.17, THAR is not doing good in the industry: 85.77% of the companies in the same industry are doing better.
A Quick Ratio of 1.17 indicates that THAR should not have too much problems paying its short term obligations.
The Quick ratio of THAR (1.17) is worse than 85.21% of its industry peers.
Industry RankSector Rank
Current Ratio 1.17
Quick Ratio 1.17
THAR Yearly Current Assets VS Current LiabilitesTHAR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

THAR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 88.78%, which is quite impressive.
EPS 1Y (TTM)88.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

THAR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.09% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y5.23%
EPS Next 2Y41.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
THAR Yearly EPS VS EstimatesTHAR Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -50 -100 -150 -200 -250

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

THAR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for THAR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
THAR Price Earnings VS Forward Price EarningsTHAR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
THAR Per share dataTHAR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

THAR's earnings are expected to grow with 41.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.09%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for THAR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THARIMMUNE INC

NASDAQ:THAR (12/1/2025, 8:00:00 PM)

After market: 2.4188 +0.06 (+2.49%)

2.36

-0.24 (-9.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12
Earnings (Next)03-25 2026-03-25/bmo
Inst Owners6.14%
Inst Owner Change688.39%
Ins Owners5.23%
Ins Owner Change43.31%
Market Cap82.69M
Revenue(TTM)N/A
Net Income(TTM)-12.01M
Analysts82.86
Price Target5.1 (116.1%)
Short Float %3.89%
Short Ratio0.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 225.08
P/tB 225.08
EV/EBITDA N/A
EPS(TTM)-6.23
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -474.8%
ROE -3269.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-179.85%
ROA(5y)-342.76%
ROE(3y)-395.91%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.17
Quick Ratio 1.17
Altman-Z -13.2
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.32%
EPS Next Y5.23%
EPS Next 2Y41.09%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-33.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-31.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.16%
OCF growth 3YN/A
OCF growth 5YN/A

THARIMMUNE INC / THAR FAQ

Can you provide the ChartMill fundamental rating for THARIMMUNE INC?

ChartMill assigns a fundamental rating of 1 / 10 to THAR.


What is the valuation status for THAR stock?

ChartMill assigns a valuation rating of 1 / 10 to THARIMMUNE INC (THAR). This can be considered as Overvalued.


Can you provide the profitability details for THARIMMUNE INC?

THARIMMUNE INC (THAR) has a profitability rating of 0 / 10.


What is the financial health of THARIMMUNE INC (THAR) stock?

The financial health rating of THARIMMUNE INC (THAR) is 2 / 10.